Education
About Us
Working with TipRanks
Follow Us
Microba Life Sciences Limited (AU:MAP)
ASX:MAP
MAP Stock Chart & Stats
AU$0.08
>-AU$0.01(-1.89%)
At close: 4:00 PM EST
AU$0.08
>-AU$0.01(-1.89%)
Day’s Range― - ―
52-Week RangeAU$0.07 - AU$0.24
Previous CloseN/A
Volume476.46K
Average Volume (3M)469.77K
Market Cap
AU$51.76M
Enterprise ValueAU$29.54M
Total Cash (Recent Filing)AU$11.74M
Total Debt (Recent Filing)AU$3.23M
Price to Earnings (P/E)―
Beta0.84
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding608,963,000
10 Day Avg. Volume548,444
30 Day Avg. Volume469,774
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)1.17
Price to Sales (P/S)2.43
P/FCF Ratio-2.56
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.21Price Target Upside162.50% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Diversified Revenue StreamsMicroba sells consumer/clinician tests, B2B sequencing/bioinformatics services and collaboration work. This multi-channel model spreads commercial risk, supports recurring and project revenue, and leverages its platform and datasets for durable demand across customers and research partners.
Low Financial LeverageA low debt-to-equity ratio provides financial flexibility and lower fixed interest costs, allowing the company to invest in R&D, lab capacity or partnerships without immediate refinancing pressure. This strengthens resilience to revenue volatility over the coming months.
Positive Free Cash Flow GrowthReported FCF growth and FCF exceeding net income indicate the business can generate cash even while accounting losses persist. That cash generation can extend runway, fund critical operations or targeted investments, and reduce near-term reliance on external capital.
Bears Say
Declining RevenueA 24% decline in revenue is a structural concern: it reduces operating leverage, constrains margins, and limits reinvestment into product development and commercialisation. If sustained over 2–6 months it undermines growth prospects and increases funding needs.
Persistent Operating LossesNegative profitability across net, EBIT and EBITDA margins signals that core operations do not cover costs. Persistent losses erode equity, suppress ROE, and limit the ability to self-fund expansion or absorb setbacks, creating structural pressure on strategic options.
Negative Operating Cash FlowNegative operating cash flow means core activities are not generating cash to sustain operations. Over months this increases dependence on financing or equity raises, constrains discretionary spending on R&D and commercialisation, and raises execution risk.
Microba Life Sciences Limited News
MAP FAQ
What was Microba Life Sciences Limited’s price range in the past 12 months?
Microba Life Sciences Limited lowest share price was AU$0.07 and its highest was AU$0.24 in the past 12 months.
What is Microba Life Sciences Limited’s market cap?
Microba Life Sciences Limited’s market cap is AU$51.76M.
When is Microba Life Sciences Limited’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Microba Life Sciences Limited’s earnings last quarter?
Currently, no data Available
Is Microba Life Sciences Limited overvalued?
According to Wall Street analysts Microba Life Sciences Limited’s price is currently Undervalued.
Does Microba Life Sciences Limited pay dividends?
Microba Life Sciences Limited does not currently pay dividends.
What is Microba Life Sciences Limited’s EPS estimate?
Microba Life Sciences Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Microba Life Sciences Limited have?
Microba Life Sciences Limited has 608,963,000 shares outstanding.
What happened to Microba Life Sciences Limited’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Microba Life Sciences Limited?
Currently, no hedge funds are holding shares in AU:MAP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Microba Life Sciences Limited Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$0.21 (162.50% Upside)
AU$0.21 (162.50% Upside)
Blogger Sentiment
Bullish
AU:MAP Sentiment 100%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-51.76%
12-Months-Change
Fundamentals
Return on Equity
-40.54%
Trailing 12-Months
Asset Growth
-18.27%
Trailing 12-Months
Company Description
Microba Life Sciences Limited
Microba Life Sciences Limited provides microbiome testing and analysis services for clinicians, consumers, and research customers in Australia, Europe, New Zealand, the United Arab Emirates, the United Kingdom, and the United States. It offers pathology, therapeutics, and diagnostics services based on the human gut microbiome; Databank, for discovery of therapeutic leads, consumer health innovations, and diagnostic biomarkers; and data-driven therapeutics platform that develops novel monoclonal microbial cell therapies for inflammatory bowel disease, cancer immunotherapy, and autoimmune diseases. The company was incorporated in 2017 and is based in Brisbane, Australia.
MAP Stock 12 Month Forecast
Average Price Target
AU$0.21
▲(162.50% Upside)
Technical Analysis
BCAL Diagnostics Limited
―
Lumos Diagnostics Holdings Ltd.
―
Cryosite Limited
―
Genetic Signatures Ltd.
―
Inoviq Ltd
―
Options Prices
Currently, No data available
---